2023
Association of SGLT‐2 Inhibitors With Treatment Satisfaction and Diabetes‐Specific and General Health Status in Adults With Cardiovascular Disease and Type 2 Diabetes
Ding Q, Spatz E, Bena J, Morrison S, Levay M, Lin H, Grey M, Edwards N, Isaacs D, West L, Combs P, Albert N. Association of SGLT‐2 Inhibitors With Treatment Satisfaction and Diabetes‐Specific and General Health Status in Adults With Cardiovascular Disease and Type 2 Diabetes. Journal Of The American Heart Association 2023, 12: e029058. PMID: 37655510, PMCID: PMC10547320, DOI: 10.1161/jaha.122.029058.Peer-Reviewed Original ResearchConceptsSodium-glucose cotransporter 2 inhibitorsGeneral health statusCardiovascular disease typesType 2 diabetesTreatment satisfactionDiabetes-specific qualityCardiovascular diseaseHealth statusDisease typeProspective observational study designPatient-reported health statusInverse probabilityNoninsulin antidiabetic medicationsSGLT-2i useSGLT-2i usersTreatment-weighted analysisCotransporter 2 inhibitorsSGLT-2 inhibitorsDiabetes treatment satisfactionObservational study designGreater reductionAntidiabetic medicationsDiabetes medicationsSecondary outcomesSymptom burden
2015
Cardiac Resynchronization Therapy in Women Versus Men
Zusterzeel R, Spatz ES, Curtis JP, Sanders WE, Selzman KA, Piña IL, Bao H, Ponirakis A, Varosy PD, Masoudi FA, Caños DA, Strauss DG. Cardiac Resynchronization Therapy in Women Versus Men. Circulation Cardiovascular Quality And Outcomes 2015, 8: s4-s11. PMID: 25714821, DOI: 10.1161/circoutcomes.114.001548.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overBundle-Branch BlockCardiac Resynchronization TherapyCardiac Resynchronization Therapy DevicesDefibrillators, ImplantableElectric CountershockFemaleHealth Status DisparitiesHeart Conduction SystemHeart FailureHumansKaplan-Meier EstimateMalePropensity ScoreProportional Hazards ModelsRegistriesRisk FactorsSex FactorsStroke VolumeTreatment OutcomeUnited StatesVentricular Function, LeftConceptsLeft bundle branch blockQRS durationImplantable cardioverter defibrillatorPatient sexDeath riskCardioverter defibrillatorBetter survivalMortality differencesNew York Heart Association class IIILeft ventricular ejection fractionWomen Versus MenCardiac resynchronization therapyVentricular ejection fractionRelative death riskBenefit of CRTLonger QRS durationShorter QRS durationBundle branch blockLower mortality riskEjection fractionHeart failureResynchronization therapyCardiac resynchronizationBranch blockMortality risk